Legal Representation
Attorney
David R. Kelly
USPTO Deadlines
Next Deadline
1351 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-04-11)
Due Date
April 11, 2029
Grace Period Ends
October 11, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 7, 2024 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Feb 7, 2024 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Apr 11, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 11, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 7, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Mar 6, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Feb 23, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 23, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 23, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 13, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 13, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 13, 2022 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Oct 19, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 17, 2022 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Oct 17, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| May 31, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| May 31, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 31, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 31, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 31, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Apr 12, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 11, 2022 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Apr 8, 2022 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Apr 8, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 22, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 20, 2021 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Oct 20, 2021 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Oct 20, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 22, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 20, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Apr 20, 2021 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Apr 20, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 24, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 22, 2020 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Oct 22, 2020 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Oct 22, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 11, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 10, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 10, 2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Apr 8, 2020 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Apr 8, 2020 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Apr 8, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 22, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 27, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 27, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 7, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 19, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jul 10, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 21, 2018 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Jun 21, 2018 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
Detailed Classifications
Class 001
Chemicals, biochemicals and reagents for use in industry and science; chemicals, biochemicals and reagents, namely, proteins for regulating, modifying or restricting gene expression; kits consisting primarily of proteins for regulating, modifying or restricting gene expression
First Use Anywhere:
20190400
First Use in Commerce:
20190400
Class 005
Chemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; biochemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; chemical reagents for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders
First Use Anywhere:
20190400
First Use in Commerce:
20190400
Class 042
Scientific research and development services in the field of medicine, pharmacology, immunology, biochemistry, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare; Therapeutic research of treatments in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular disease which are under development or have completed development; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use
First Use Anywhere:
Jan 1, 2018
First Use in Commerce:
Jan 1, 2018
Class 044
Medical services; Medical services, namely, genetic engineering, biopharmaceuticals and gene therapy services; Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; Medical services, namely, providing medical therapy treatments which are under development or have completed development for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular diseases
First Use Anywhere:
Jan 1, 2018
First Use in Commerce:
Jan 1, 2018
Class 045
Technology transfer services, namely, licensing of intellectual property
First Use Anywhere:
Jan 1, 2018
First Use in Commerce:
Jan 1, 2018
Classification
International Classes
001
005
042
044
045